The Biotech space remained a key area of investors’ focus with label expansion of a few prominent drugs and pipeline updates on a few others. While Amgen obtained the FDA approval for Prolia and Repatha, Exelixis also obtained approval for its lead drug Cabometyx for the first-line treatment of kidney cancer in Europe.
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться